SUPN News and Press, Supernus Pharmaceuticals Inc. From 04/13/21

iRhythm continues to trade lower as analysts evaluate the impact of Novitas rate update on the company. Meanwhile, the recent FDA approvals have led Truist Securities to upgrade Bristol Myers.iRhythm downgraded at BTIG on uncertain outlookThe revision of Novitas reimbursement rates ...

It has been one year since the markets bottomed in March of 2020 due to COVID. Markets have rebounded beyond most investors’ expectations, with growth and tech stealing much of the spotlight. The “rotation into value” narrative has recently gained some tractio...

On Friday afternoon, Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the U.S. Food and Drug Administration (FDA) had approved Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients between the ages of 6 to 17. As a result of this re...

Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Monster debutGood news for the movie industry has finally arrived as tentpole Godzilla vs. Kong gave a shot in the arm for theaters and Hollywood. The film...

The FDA has approved Supernus Pharmaceuticals' (SUPN) Qelbree (SPN-812) (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder ((ADHD)) in pediatric patients 6 to 17 years of age. The approval of Qelbree is supported by data from a development pro...

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: S...

Supernus Pharmaceuticals (NASDAQ: SUPN) , Corcept Therapeutics (NASDAQ: CORT) , and Catalyst Pharmaceuticals (NASDAQ: CPRX) don't have much in common. But it does so happen that they're all in the healthcare space, trade for less than $26 per share, and have the pote...

Today, we revisit biopharma concern Supernus Pharmaceuticals whose just reported 4th quarter results that triggered a near 10% selloff in its stock. However, the company reported solid results for the quarter and year and navigated the impacts of the pandemic quite well in 2020. I...

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2020 Earnings Conference Call February 25, 2021, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Jack Khattar - Founder, President, CEO, Secretary & Director James Kelly - EVP & CFO Conference Call Participants David Steinberg - ...